J-ALEX: control of CNS disease
Kim, et al. WCLC 2016 (Abs. MA07.03)
Time (months)
Appearance-free rate (%)
80
60
40
20
0
100
0
27
24
21
18
15
12
6
Time to appearance of CNS disease in
patients
without
CNS mets at baseline
9
3
1
Alectinib (n=89; 3.4% with event)
Crizotinib (n=75; 14.7% with event)
HR=0.17 (0.05–0.60)
p=0.0019
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
